DORA: Platinum Treated Triple Negative Breast Cancer - Clinical Trial
What is the Purpose of this Study?
Who Can Participate in the Study?
Women age 21 or older who:
- Have breast cancer that is metastatic (has spread) and is triple negative (does not have high levels of HER2 or HR proteins)
- Are currently receiving treatment with cisplatin or carboplatin
What is Involved?
If you choose to join this study, you will:
- Be randomly assigned (like the flip of a coin) to one of two treatment groups:
--- Olaparib alone or
--- Olaparib in combination with durvalumab
- Get every 28 days
- Come to the Duke Cancer Center clinic every 4 weeks for a physical exam, blood test, to see how you are doing and to get the next dose of study drug(s).
Each clinic visit will last 1-8 hours.
You can stay in the study for as long as the study drugs appear to the study doctor to be working for you.